|
1
|
Farrell GC and Larter CZ: Nonalcoholic
fatty liver disease: From steatosis to cirrhosis. Hepatology.
43:2948–S112. 2006. View Article : Google Scholar
|
|
2
|
Angulo P: Nonalcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanyal AJ, Neuschwander-Tetri BA and
Tonascia L: End points must be clinically meaningful for drug
development in nonalcoholic fatty liver disease. Gastroenterology.
150:11–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Younossi ZM, Koenig AB, Abdelatif D, Fazel
Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty
liver disease-Meta-analytic assessment of prevalence, incidence,
and outcomes. Hepatology. 64:73–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dulai PS, Singh S, Patel J, Soni M, Prokop
LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, et al:
Increased risk of mortality by fibrosis stage in nonalcoholic fatty
liver disease: Systematic review and meta-analysis. Hepatology.
65:1557–1565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Angulo P, Kleiner DE, Dam-Larsen S, Adams
LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC,
Lafferty HD, Stahler A, et al: Liver fibrosis, but No other
histologic features, is associated with long-term outcomes of
patients with nonalcoholic fatty liver disease. Gastroenterology.
149:389–397 e10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Erickson LA, Ginsberg MH and Loskutoff DJ:
Detection and partial characterization of an inhibitor of
plasminogen activator in human platelets. J Clin Invest.
74:1465–1472. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Providence KM and Higgins PJ: PAI-1
expression is required for epithelial cell migration in two
distinct phases of in vitro wound repair. J Cell Physiol.
200:297–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toriseva M and Kähäri VM: Proteinases in
cutaneous wound healing. Cell Mol Life Sci. 66:203–224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lazar MH, Christensen PJ, Du M, Yu B,
Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH and Sisson
TH: Plasminogen activator inhibitor-1 impairs alveolar epithelial
repair by binding to vitronectin. Am J Respir Cell Mol Biol.
31:672–678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takeshita K, Hayashi M, Iino S, Kondo T,
Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, et al:
Increased expression of plasminogen activator inhibitor-1 in
cardiomyocytes contributes to cardiac fibrosis after myocardial
infarction. Am J Pathol. 164:449–456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma LJ and Fogo AB: PAI-1 and kidney
fibrosis. Front Biosci (Landmark Ed). 14:2028–2041. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clouthier DE, Comerford SA and Hammer RE:
Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like
syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest.
100:2697–2713. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Zhang Y and Heuckeroth RO: PAI-1
deficiency reduces liver fibrosis after bile duct ligation in mice
through activation of tPA. FEBS Lett. 581:3098–3104. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ajmera V, Perito ER, Bass NM, Terrault NA,
Yates KP, Gill R, Loomba R, Diehl AM and Aouizerat BE; NASH
Clinical Research Network, : Novel plasma biomarkers associated
with liver disease severity in adults with nonalcoholic fatty liver
disease. Hepatology. 65:65–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu PF, Chen H, Zhong W, Lin Y, Zhang X,
Chen YX and Xie WF: Adenovirus-mediated transfer of siRNA against
PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol.
51:102–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Izuhara Y, Yamaoka N, Kodama H, Dan T,
Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C and
Miyata T: A novel inhibitor of plasminogen activator inhibitor-1
provides antithrombotic benefits devoid of bleeding effect in
nonhuman primates. J Cereb Blood Flow Metab. 30:904–912. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tashiro Y, Nishida C, Sato-Kusubata K,
Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y,
Dan T, et al: Inhibition of PAI-1 induces neutrophil-driven
neoangiogenesis and promotes tissue regeneration via production of
angiocrine factors in mice. Blood. 119:6382–6393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Imai J, Yahata T, Ichikawa H, Ibrahim AA,
Yazawa M, Sumiyoshi H, Inagaki Y, Matsushima M, Suzuki T, Mine T,
Ando K, et al: Inhibition of plasminogen activator inhibitor-1
attenuates against intestinal fibrosis in mice. Intest Res.
18:219–228. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SM, Dorotea D, Jung I, Nakabayashi T,
Miyata T and Ha H: TM5441, a plasminogen activator inhibitor-1
inhibitor, protects against high fat diet-induced non-alcoholic
fatty liver disease. Oncotarget. 8:89746–89760. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Henkel AS, Khan SS, Olivares S, Miyata T
and Vaughan DE: Inhibition of plasminogen activator inhibitor 1
attenuates hepatic steatosis but does not prevent progressive
nonalcoholic steatohepatitis in mice. Hepatol Commun. 2:1479–1492.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Katz A, Nambi SS, Mather K, Baron AD,
Follmann DA, Sullivan G and Quon MJ: Quantitative insulin
sensitivity check index: A simple, accurate method for assessing
insulin sensitivity in humans. J Clin Endocrinol Metab.
85:2402–2410. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kleiner DE, Brunt EM, Van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaji K, Yoshiji H, Kitade M, Ikenaka Y,
Noguchi R, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Moriya K, et
al: Impact of insulin resistance on the progression of chronic
liver diseases. Int J Mol Med. 22:801–808. 2008.PubMed/NCBI
|
|
25
|
Tsuchida T and Friedman SL: Mechanisms of
hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol.
14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozutsumi T, Namisaki T, Shimozato N, Kaji
K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, et
al: Combined treatment with sodium-glucose cotransporter-2
inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor
(teneligliptin) alleviates NASH progression in A non-diabetic rat
model of steatohepatitis. Int J Mol Sci. 21:21642020. View Article : Google Scholar
|
|
27
|
Gleizes PE, Munger JS, Nunes I, Harpel JG,
Mazzieri R, Noguera I and Rifkin DB: TGF-beta latency: Biological
significance and mechanisms of activation. Stem Cells. 15:190–197.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mulligan-Kehoe MJ, Schwartz GN and
Zacharski LR: The functions of plasminogen activator inhibitor-1:
Do we have all the pieces of PAI? Thromb Res. 117:483–486. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bajou K, Noël A, Gerard RD, Masson V,
Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen
D and Foidart JM: Absence of host plasminogen activator inhibitor 1
prevents cancer invasion and vascularization. Nat Med. 4:923–928.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang LP, Takahara T, Yata Y, Furui K, Jin
B, Kawada N and Watanabe A: Increased expression of plasminogen
activator and plasminogen activator inhibitor during liver
fibrogenesis of rats: Role of stellate cells. J Hepatol.
31:703–711. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seki T, Imai H, Uno S, Ariga T and
Gelehrter TD: Production of tissue-type plasminogen activator
(t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly
cirrhotic rat liver. Thromb Haemost. 75:801–807. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leyland H, Gentry J, Arthur MJ and Benyon
RC: The plasminogen-activating system in hepatic stellate cells.
Hepatology. 24:1172–1178. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dennler S, Itoh S, Vivien D, ten Dijke P,
Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to
critical TGF beta-inducible elements in the promoter of human
plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091–3100.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okada H, Woodcock-Mitchell J, Mitchell J,
Sakamoto T, Marutsuka K, Sobel BE and Fujii S: Induction of
plasminogen activator inhibitor type 1 and type 1 collagen
expression in rat cardiac microvascular endothelial cells by
interleukin-1 and its dependence on oxygen-centered free radicals.
Circulation. 97:2175–2182. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crandall DL, Groeling TM, Busler DE and
Antrilli TM: Release of PAI-1 by human preadipocytes and adipocytes
independent of insulin and IGF-1. Biochem Biophys Res Commun.
279:984–988. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wilkins-Port CE, Ye Q, Mazurkiewicz JE and
Higgins PJ: TGF-beta1 + EGF-initiated invasive potential in
transformed human keratinocytes is coupled to a
plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: Role for
PAI-1. Cancer Res. 69:4081–4091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Su EJ, Fredriksson L, Schielke GP,
Eriksson U and Lawrence DA: Tissue plasminogen activator-mediated
PDGF signaling and neurovascular coupling in stroke. J Thromb
Haemost. 7 (Suppl 1):S155–S158. 2009. View Article : Google Scholar
|
|
38
|
Hellerbrand C, Stefanovic B, Giordano F,
Burchardt ER and Brenner DA: The role of TGFbeta1 in initiating
hepatic stellate cell activation in vivo. J Hepatol. 30:77–87.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kanzler S, Lohse AW, Keil A, Henninger J,
Dienes HP, Schirmacher P, Rose-John S, zum Büschenfelde KH and
Blessing M: TGF-beta1 in liver fibrosis: An inducible transgenic
mouse model to study liver fibrogenesis. Am J Physiol.
276:G1059–G1068. 1999.PubMed/NCBI
|
|
40
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Motojima M, Kakuchi J and Yoshioka T:
Association of TGF-beta signaling in angiotensin II-induced PAI-1
mRNA upregulation in mesangial cells: Role of PKC. Biochim Biophys
Acta. 1449:217–226. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dong C, Zhu S, Alvarez RJ and
Goldschmidt-Clermont PJ: Angiotensin II induces PAI-1 expression
through MAP kinase-dependent, but TGF beta and PI3
kinase-independent pathway. J Heart Lung Transplant. 20:226–227.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Samarakoon R, Higgins SP, Higgins CE and
Higgins PJ: TGF-beta1-induced plasminogen activator inhibitor-1
expression in vascular smooth muscle cells requires pp60(c-src)/
EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol. 44:527–538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chanda D, Lee CH, Kim YH, Noh JR, Kim DK,
Park JH, Hwang JH, Lee MR, Jeong KH, Lee IK, et al: Fenofibrate
differentially regulates plasminogen activator inhibitor-1 gene
expression via adenosine monophosphate-activated protein
kinase-dependent induction of orphan nuclear receptor small
heterodimer partner. Hepatology. 50:880–892. 2009. View Article : Google Scholar : PubMed/NCBI
|
